Dublin, Feb. 19, 2019 (GLOBE NEWSWIRE) -- The "Global Cancer Immunotherapy Market: Focus on Pharmaceutical Products, Therapeutic Indication, Competitive Landscape and Region - Analysis and Forecast, 2018-2028" report has been added to ResearchAndMarkets.com's offering.

The global cancer immunotherapy market was valued at $39.86 billion in 2017 and is anticipated to reach $170.70 billion by 2028.

The rising prevalence of cancer around the world and high unmet medical needs of patients with cancer are stimulators for the growth of the cancer immunotherapy market. In addition, the advancements in precision medicine for immuno-oncology and rise in expenditure by pharmaceutical companies on R&D for cancer treatments, are contributing to the rise in demand for cancer immunotherapy as a treatment for cancer.

The scope of the report is centered upon a detailed study of the solutions allied with cancer immunotherapy market which involves immune-oncology drugs used in different therapeutic applications for cancer treatment. The global cancer immunotherapy market is segmented into three different parts: by products', by therapeutic indication', and by region'. The global market value for cancer immunotherapy was estimated using these three different approaches and was validated against one another. These segments are further segmented into several sub-segments to ease the market estimation.

Based on products, the market can be sub-segmented into monoclonal antibodies, check point inhibitors, cancer vaccine, and others. The market for monoclonal antibodies dominates the market in terms of revenue. The growth of the monoclonal antibodies market is accredited to the efficacy of these targeted antibodies, rising demand for advanced oncology medicines along with an increase in the research and development facilities globally. However, Check Point Inhibitors exhibit a higher growth rate as they have shown to be more efficacious and have less toxicity as compared to other product classes. These products have a novel mechanism of action which have revolutionized the cancer immunotherapy market.

Based on therapeutic indication, the market can be classified into seven major cancer types, which include breast cancer, melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, renal cell carcinoma, gastric cancer, and others. Among the different types of cancers, breast cancer is the leading contributor to metastatic cancer treatment market, while the highest CAGR is expected to be registered by NSCLC during the forecast period from 2018 to 2028.

North America leads the market in terms of revenue, followed by Europe. Within North America, the U.S. generated almost 96% of the total revenue share, and the rest 4 % of the revenue was generated by Canada in 2017. Within Europe, Germany dominated the market in 2017 with a revenue share of 16.73%. However, the market for Asia-pacific region is expected to demonstrate the highest growth rate, during the forecast period from 2018 to 2028, as compared to other regions.

The cancer immunotherapy market has a promising potential for growth in the coming years. The report provides an in-depth SWOT analysis of different key players of the market, supported by an extensive financial summary of each company.

The key players of the market are

• Aduro Biotech
• Amgen
• Astrazeneca Plc
• Bristol-Myers Squibb
• Celgene Corporation
• Dnatrix Therapeutics
• Eli Lilly And Company
• F. Hoffmann La Roche
• Fate Therapeutics
• Gilead Sciences, Inc.
• Iovance Biotherapeutics, Inc.
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis Ag
• Pfizer, Inc.
• Precision Biosciences, Inc.

Key Topics Covered:

Executive Summary

1 Market Overview
1.1 Cancer Immunotherapy
1.2 Types of Cancer Immunotherapy

2 Market Dynamics
2.1 Drivers
2.1.1 Rising Prevalence of Cancer
2.1.2 Unmet Medical Needs of Cancer Patients
2.1.3 Rising R&D Expenditure in the Immuno-Oncology Segment
2.1.4 Advancement of Precision Medicine in Immuno-oncology
2.2 Restraints
2.2.1 High Cost of Treatment
2.2.2 Adverse Effects of Immunotherapy Treatment
2.3 Opportunities
2.3.1 Development of Targeted Therapy
2.3.2 Development of Healthcare Infrastructure and Reimbursement Policies in Emerging Economies
2.3.3 Combination Therapy

3 Competitive Landscape
3.1 Key Developmental Strategies
3.1.1 Product Approval
3.1.2 Agreements, Collaborations and Partnerships
3.1.3 Clinical Study
3.1.4 Regulatory Designation
3.1.5 Acquisition
3.1.6 Others
3.2 Market Share Analysis

4 Industry Insights
4.1 Regulatory Organizations/ Associations/ Consortiums
4.2 Patent Landscape
4.3 Regulatory Designations

5 Global Cancer Immunotherapy Market (By Product)
5.1 Monoclonal Antibodies
5.2 Checkpoint Inhibitors
5.2.1 CTLA-4 Inhibitors
5.2.2 PD-L1 Inhibitors/ PD-1 Inhibitors
5.3 Cancer Vaccines
5.3.1 Other Cancer Therapies
5.3.1.1 Oncolytic Viruses
5.3.1.2 Adoptive Cell Transfer

6 Global Cancer Immunotherapy Market (by Therapeutic Indication)
6.1 Breast Cancer
6.2 Non-Small Cell Lung Cancer (NSCLC)
6.3 Melanoma
6.4 Colorectal Cancer
6.5 Renal Cell Carcinoma
6.6 Gastric Cancer
6.7 Others

7 Global Cancer Immunotherapy Market (by Region)

8 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/bjdfc6/global_170_bn?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs